The findings, presented at the 2020 ASCO Virtual Scientific Program, are the first to show benefit with pembrolizumab in patients with advanced colorectal cancer when used as a front-line therapy.
The CLL expert discussed the possibility of venetoclax plus dose-adjusted R-EPOCH becoming a new treatment approach in patients with CLL who developed Richter’s Syndrome.
Jane L. Meisel, MD, discusses the clinical implications of the TAILORx trial and how it has affected practice.
The MSK expert discussed the need for targeted testing for the Ashkenazi Jewish BRCA mutations in the US healthcare system.
The most common, expected, and reversible treatment-emergent adverse event associated with the agent was cytokine release syndrome.
When compared to currently approved therapies, KTE-X19 demonstrated comparable pharmacologic and clinical outcomes in patients with high-risk MCL characteristics versus lower-risk characteristics defined by tumor protein TP53 mutation or high Ki-67 proliferation index.
The MD Anderson Cancer Center expert discussed why there is an unmet need for more treatments in patients with IDH1-mutated acute myeloid leukemia.
Final data analysis of SPARTAN trial demonstrates large benefit in overall survival when compared with ADT plus placebo.
Overall survival (OS) benefit derived from frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer was further improved after at least 12 months of follow-up.
Results showed that axicabtagene ciloleucel demonstrated significant and durable clinical benefit in patients with relapsed or refractory indolent non-Hodgkin lymphoma.